⌕
4D Molecular Therapeutics · FDMT · Nasdaq
Tenet 52 · Mixed
Compare
$10.79−4.43%At closeTenet 52 · Mixed
$10.79−0.50 (−4.43%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

4D Molecular Therapeutics (FDMT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~47.4%/yr (FY21→FY25), net margin −164.4%. Worth your attention in FY25: Share count (+108.9%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
85.2
FY21→FY25CAGR +47.4%/yr
Net income ($M)▲12.9%
−140.1
FY21→FY25CAGR —
Free cash flow ($M)▲20.8%
−109.6
FY21→FY25CAGR —
Diluted EPS▲18.8%
−2.42
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+108.9%

27.7mn → 57.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$536.0K

−85.8% YoY in FY25 · 0.6% of revenue.

Returns vs FCF
n/m

$0.0M returned vs $−109.6M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)85.2Revenue0.0COGS85.2Gross profit−195.7R&D−49.1SG&A−159.5Op income19.4Tax & other−140.1Net income

-164¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -164.4% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
96,077.085,209.00.020,723.03,129.018,038.0—+47.4%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
96,077.085,209.00.020,723.03,129.018,038.0—+47.4%
Research & development
260,646.0195,696.0141,299.097,096.080,253.061,360.0▲38.5%+33.6%
Selling, general & admin
52,565.049,060.046,579.036,494.032,908.028,011.0▲5.3%+15.0%
Total operating expenses
313,211.0244,756.0187,878.0133,590.0113,161.089,371.0▲30.3%+28.6%
Operating incomefeeds ROC rank
−217,148.0−159,547.0−187,841.0−112,867.0−110,032.0−71,333.0▲15.1%—
Other income, net
16,793.019,438.026,973.012,030.02,538.016.0——
Pretax income
−200,355.0−140,109.0−160,868.0−100,837.0−107,494.0−71,317.0▲12.9%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−200,355.0−140,109.0−160,868.0−100,837.0−107,494.0−71,317.0▲12.9%—
Per share
Diluted EPSbuyback-sensitive
−2.70−2.42−2.98−2.58−3.32−2.57▲18.8%—
Diluted shares (mn)
72.2557.9353.9439.1332.3527.73▲7.4%+20.2%
Margins
Gross margin81st pct in Healthcare
100.0%100.0%—100.0%100.0%100.0%——
Operating margin
−226.0%−187.2%—−544.6%−3516.5%−395.5%——
Net margin19th pct in Healthcare
−208.5%−164.4%—−486.6%−3435.4%−395.4%——
† TTM = trailing four quarters through 2026-09-30.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-18 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was 4D Molecular Therapeutics' net income?

4D Molecular Therapeutics reported net income of −$140.1M in fiscal 2025, a net margin of −164.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.